Search Results - "SCHMIDINGER, M."

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Escudier, B, Porta, C, Schmidinger, M, Rioux-Leclercq, N, Bex, A, Khoo, V, Grünwald, V, Gillessen, S, Horwich, A

Get full text

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Escudier, B, Porta, C, Schmidinger, M, Rioux-Leclercq, N, Bex, A, Khoo, V, Gruenvald, V, Horwich, A

Get full text

ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma by Powles, T., Albiges, L., Bex, A., Grünwald, V., Porta, C., Procopio, G., Schmidinger, M., Suárez, C., de Velasco, G.

“…•This special article provides key recommendations on the immunotherapy treatments of renal cell carcinoma.•Recommendations are based on available scientific…”
Get full text

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Escudier, B, Porta, C, Schmidinger, M, Algaba, F, Patard, J J, Khoo, V, Eisen, T, Horwich, A

Get full text

Clinical biomarkers of response in advanced renal cell carcinoma by Ravaud, A., Schmidinger, M.

“…There are now a range of effective targeted agents available for the first- and second-line treatment of advanced renal cell carcinoma (RCC). However, patients…”
Get full text

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma by Choueiri, T.K., Motzer, R.J., Rini, B.I., Haanen, J., Campbell, M.T., Venugopal, B., Kollmannsberger, C., Gravis-Mescam, G., Uemura, M., Lee, J.L., Grimm, M.-O., Gurney, H., Schmidinger, M., Larkin, J., Atkins, M.B., Pal, S.K., Wang, J., Mariani, M., Krishnaswami, S., Cislo, P., Chudnovsky, A., Fowst, C., Huang, B., di Pietro, A., Albiges, L.

“…The phase 3 JAVELIN Renal 101 trial (NCT02684006) demonstrated significantly improved progression-free survival (PFS) with first-line avelumab plus axitinib…”
Get full text

Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up by Powles, T, Albiges, L, Bex, A, Comperat, E, Grünwald, V, Kanesvaran, R, Kitamura, H, McKay, R, Porta, C, Procopio, G, Schmidinger, M, Suarez, C, Teoh, J, de Velasco, G, Young, M, Gillessen, S

Get more information

Dual immune checkpoint inhibition in metastatic renal cell carcinoma: Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial by Schmidinger, M., Shariat, S.F., Fajkovic, H.

Get full text

Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma by Haanen, J.B.A.G., Larkin, J., Choueiri, T.K., Albiges, L., Rini, B.I., Atkins, M.B., Schmidinger, M., Penkov, K., Michelon, E., Wang, J., Mariani, M., di Pietro, A., Motzer, R.J.

“…We report updated data for avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma from the third interim analysis of the phase…”
Get full text

JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC) by Motzer, R.J., Penkov, K., Haanen, J.B.A.G., Rini, B.I., Albiges, L., Campbell, M.T., Kollmannsberger, C.K., Negrier, S., Uemura, M., Lee, J.L., Gurney, H., Berger, R., Schmidinger, M., Larkin, J., Atkins, M.B., Wang, J., Robbins, P.B., Chudnovsky, A., Di Pietro, A., Choueiri, T.K.

Get full text

Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101 by Tomita, Y., Motzer, R.J., Choueiri, T.K., Rini, B.I., Miyake, H., Uemura, H., Albiges, L., Fujii, Y., Umeyama, Y., Wang, J., Mariani, M., Schmidinger, M.

“…In the phase III JAVELIN Renal 101 trial, first-line avelumab plus axitinib demonstrated a progression-free survival (PFS) and objective response rate (ORR)…”
Get full text

Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable by VOGL, U. M, ZEHETGRUBER, H, DOMINKUS, M, HEJNA, M, ZIELINSKI, C. C, HAITEL, A, SCHMIDINGER, M

“…Prognostic and predictive factors in patients with metastatic renal cell carcinoma (MRCC) have been evaluated from untreated patients or patients on several…”
Get full text

First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts by Aeppli, S., Schmaus, M., Eisen, T., Escudier, B., Grünwald, V., Larkin, J., McDermott, D., Oldenburg, J., Porta, C., Rini, B.I., Schmidinger, M., Sternberg, C.N., Rothermundt, C., Putora, P.M.

“…The treatment landscape of metastatic clear cell renal cell carcinoma (mccRCC) has been transformed by targeted therapies with tyrosine kinase inhibitors (TKI)…”
Get full text

Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines by Resch, I., Bruchbacher, A., Franke, J., Fajkovic, H., Remzi, M., Shariat, S.F., Schmidinger, M.

“…Immune checkpoint inhibitors (ICIs) have led to a paradigm change in the management of metastatic renal cell carcinoma (mRCC). Prospective trials have focused…”
Get full text

Real-world effectiveness of pazopanib in patients with intermediate prognostic risk advanced renal cell carcinoma (PRINCIPAL study) by Procopio, G., Bamias, A., Schmidinger, M., Hawkins, R., Rodriguez Sanchez, A., Vazquez, S., Srihari, N., Kalofonos, H., Bono, P., Pisal, C., Hirschberg, Y., Dezzani, L., Ahmad, Q., Suarez Rodriguez, C., Jonasch, E.

Get full text

Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101 by Tomita, Y., Motzer, R.J., Choueiri, T.K., Rini, B.I., Miyake, H., Oya, M., Albiges, L., Aizawa, M., Umeyama, Y., Wang, J., di Pietro, A., Schmidinger, M.

“…In the phase III JAVELIN Renal 101 trial, first-line avelumab + axitinib improved progression-free survival (PFS) and objective response rate versus sunitinib…”
Get full text

Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases by Steindl, A., Alpar, D., Heller, G., Mair, M.J., Gatterbauer, B., Dieckmann, K., Widhalm, G., Hainfellner, J.A., Schmidinger, M., Bock, C., Müllauer, L., Preusser, M., Berghoff, A.S.

“…Tumor mutational burden (TMB) and density of tumor-infiltrating lymphocytes (TIL) have been postulated as predictive biomarkers for immunotherapy. Therefore,…”
Get full text

The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? by Hejna, M., Schmidinger, M., Raderer, M.

“…Background Somatostatin (SST) analogues represent a novel approach for the treatment of certain cancers. The objective of this article is to summarise the…”
Get full text

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma by Kanesvaran, R., Porta, C., Wong, A., Powles, T., Ng, Q.S., Schmidinger, M., Ye, D., Malhotra, H., Miura, Y., Lee, J.L., Chong, F.L.T., Pu, Y.-S., Yen, C.-C., Saad, M., Lee, H.J., Kitamura, H., Bhattacharyya, G.S., Curigliano, G., Poon, E., Choo, S.P., Peters, S., Lim, E., Yoshino, T., Pentheroudakis, G.

“…The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of renal…”
Get full text

Second-line treatment for metastatic clear cell renal cell cancer: experts’ consensus algorithms by Rothermundt, C., von Rappard, J., Eisen, T., Escudier, B., Grünwald, V., Larkin, J., McDermott, D., Oldenburg, J., Porta, C., Rini, B., Schmidinger, M., Sternberg, C. N., Putora, P. M.

“…Background Second-line systemic treatment options for metastatic clear cell renal cell cancer (mccRCC) are diverse and treatment strategies are variable among…”
Get full text